DK1736158T3 - Anvendel af 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin samt de fysiologiske acceptable salte deraf - Google Patents

Anvendel af 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin samt de fysiologiske acceptable salte deraf

Info

Publication number
DK1736158T3
DK1736158T3 DK06017231T DK06017231T DK1736158T3 DK 1736158 T3 DK1736158 T3 DK 1736158T3 DK 06017231 T DK06017231 T DK 06017231T DK 06017231 T DK06017231 T DK 06017231T DK 1736158 T3 DK1736158 T3 DK 1736158T3
Authority
DK
Denmark
Prior art keywords
carbamoylbenzofuran
cyanoindol
piperazine
butyl
acceptable salts
Prior art date
Application number
DK06017231T
Other languages
Danish (da)
English (en)
Inventor
Gerd Bartoszyk
Christoph Seyfried
Amsterdam Christoph Van
Henning Boettcher
Ewen Sedman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1736158(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK1736158T3 publication Critical patent/DK1736158T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK06017231T 1999-05-27 2000-05-16 Anvendel af 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin samt de fysiologiske acceptable salte deraf DK1736158T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99109295 1999-05-27
PCT/EP2000/004376 WO2000072832A2 (en) 1999-05-27 2000-05-16 Novel use of 1-[4-(cyanoindol-3yl)butyl]-4-(carbamoyl-benzofuran-5yl)-piperazine and its physiologically acceptable salts

Publications (1)

Publication Number Publication Date
DK1736158T3 true DK1736158T3 (da) 2009-11-02

Family

ID=8238153

Family Applications (3)

Application Number Title Priority Date Filing Date
DK06017231T DK1736158T3 (da) 1999-05-27 2000-05-16 Anvendel af 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin samt de fysiologiske acceptable salte deraf
DK04001441T DK1410800T3 (da) 1999-05-27 2000-05-16 Anvendelse af 1-[4-(5-cyanoindol-3-yl)butyl]-4(2-carbamoyl-benzofuran-5-yl)-piperazin og de fysiologisk acceptable salte deraf
DK00935031T DK1185272T3 (da) 1999-05-27 2000-05-16 Hidtil ukendt anvendelse af 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazin og dets fysiologisk acceptable salte til behandling af bipolære lidelser og mani

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK04001441T DK1410800T3 (da) 1999-05-27 2000-05-16 Anvendelse af 1-[4-(5-cyanoindol-3-yl)butyl]-4(2-carbamoyl-benzofuran-5-yl)-piperazin og de fysiologisk acceptable salte deraf
DK00935031T DK1185272T3 (da) 1999-05-27 2000-05-16 Hidtil ukendt anvendelse af 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazin og dets fysiologisk acceptable salte til behandling af bipolære lidelser og mani

Country Status (31)

Country Link
US (4) US6900212B1 (enExample)
EP (3) EP1410800B1 (enExample)
JP (2) JP4884588B2 (enExample)
KR (1) KR100683367B1 (enExample)
CN (3) CN101869565A (enExample)
AR (1) AR024112A1 (enExample)
AT (3) ATE263564T1 (enExample)
AU (1) AU771778B2 (enExample)
BR (1) BR0010948A (enExample)
CA (3) CA2694866A1 (enExample)
CY (2) CY1105750T1 (enExample)
CZ (1) CZ295623B6 (enExample)
DE (3) DE60042710D1 (enExample)
DK (3) DK1736158T3 (enExample)
ES (3) ES2271707T3 (enExample)
HK (1) HK1048444B (enExample)
HU (1) HU229059B1 (enExample)
IL (2) IL146707A0 (enExample)
MX (1) MXPA01012172A (enExample)
MY (1) MY135627A (enExample)
NO (2) NO322120B1 (enExample)
PL (3) PL199516B1 (enExample)
PT (3) PT1410800E (enExample)
RU (1) RU2237477C2 (enExample)
SI (2) SI1410800T1 (enExample)
SK (1) SK287851B6 (enExample)
TR (1) TR200103361T2 (enExample)
TW (1) TW518218B (enExample)
UA (1) UA74337C2 (enExample)
WO (1) WO2000072832A2 (enExample)
ZA (1) ZA200110485B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76130C2 (en) 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
DE10112151A1 (de) * 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
UA76758C2 (uk) 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10305739A1 (de) * 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
US20040192730A1 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction
US7893261B2 (en) 2004-03-26 2011-02-22 Baylor University Serotonin reuptake inhibitors
MX2008015226A (es) 2006-05-30 2008-12-12 Astrazeneca Ab Derivados de 1,3,4-oxadiazol como inhibidores de dgat1.
EP2234978B1 (en) 2007-12-20 2015-02-25 AstraZeneca AB Carbamoyl compounds as dgat1 inhibitors 190
RU2011152517A (ru) 2009-06-19 2013-07-27 Астразенека Аб Пиразинкарбоксамиды в качестве ингибиторов dgat1
RU2556585C2 (ru) 2009-11-06 2015-07-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома дефицита внимания и гиперактивности
ES2743153T3 (es) 2009-11-06 2020-02-18 Sk Biopharmaceuticals Co Ltd Métodos para tratar el síndrome de fibromialgia
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
US9708300B2 (en) 2011-03-20 2017-07-18 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
EP2861586A4 (en) 2012-06-13 2015-11-11 Apotex Inc FORMS OF VILAZODONE AND METHODS OF PREPARATION THEREOF
CN102860993A (zh) * 2012-10-16 2013-01-09 北京诚创思达医药科技有限公司 一种盐酸维拉唑酮快速释放片剂及其制备方法
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
CA3128321C (en) 2013-01-22 2023-12-05 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP2824104A1 (en) 2013-07-12 2015-01-14 Sandoz AG Process for the preparation of form III of Vilazodone hydrochloride
KR20240068766A (ko) * 2015-05-22 2024-05-17 비스타젠 쎄라퓨틱스, 인크. L-４-클로로키누레닌의 치료적 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
DE19514567A1 (de) 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5914394A (en) * 1997-03-27 1999-06-22 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6470933B1 (en) * 1998-03-09 2002-10-29 Pirelli Pneumatici S.P.A. Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire
FR2781671A1 (fr) 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1291660A3 (en) * 2001-09-11 2003-05-28 Koyo Seiko Co., Ltd. Magnetic pulser ring, magnetizing device and method, and bearing unit having a magnetic pulser ring
FR2844591B1 (fr) * 2002-09-13 2005-04-15 Arvinmeritor Light Vehicle Sys Dispositif de determination du deplacement d'un arbre

Also Published As

Publication number Publication date
US20080119484A1 (en) 2008-05-22
ATE438399T1 (de) 2009-08-15
EP1410800A1 (en) 2004-04-21
DE60030338T2 (de) 2007-08-16
MY135627A (en) 2008-05-30
DE60042710D1 (de) 2009-09-17
UA74337C2 (uk) 2005-12-15
IL146707A0 (en) 2002-07-25
HUP0201275A2 (en) 2002-08-28
CN1679577A (zh) 2005-10-12
WO2000072832A2 (en) 2000-12-07
EP1736158B1 (en) 2009-08-05
CA2694866A1 (en) 2000-12-07
PT1185272E (pt) 2004-08-31
JP2003500441A (ja) 2003-01-07
AU771778B2 (en) 2004-04-01
NO20015746L (no) 2001-11-26
IL146707A (en) 2007-06-03
CY1109472T1 (el) 2012-05-23
CA2615271C (en) 2011-02-15
PL199650B1 (pl) 2008-10-31
DE60030338D1 (de) 2006-10-05
BR0010948A (pt) 2002-04-23
NO324230B1 (no) 2007-09-10
KR100683367B1 (ko) 2007-02-15
DE60009697T2 (de) 2005-04-14
PL352373A1 (en) 2003-08-25
CN1361692A (zh) 2002-07-31
NO20015746D0 (no) 2001-11-26
US20050113386A1 (en) 2005-05-26
US6900212B1 (en) 2005-05-31
HK1048444B (zh) 2005-12-09
WO2000072832A3 (en) 2001-12-20
ES2271707T3 (es) 2007-04-16
HU229059B1 (en) 2013-07-29
EP1736158A3 (en) 2007-01-03
ATE337008T1 (de) 2006-09-15
SI1410800T1 (sl) 2007-02-28
CA2372668C (en) 2009-11-03
EP1736158A2 (en) 2006-12-27
DK1410800T3 (da) 2006-12-27
US7642261B2 (en) 2010-01-05
CN1198618C (zh) 2005-04-27
AR024112A1 (es) 2002-09-04
EP1410800B1 (en) 2006-08-23
TW518218B (en) 2003-01-21
PT1410800E (pt) 2007-01-31
CN101869565A (zh) 2010-10-27
DE60009697D1 (de) 2004-05-13
JP2011148799A (ja) 2011-08-04
EP1185272A2 (en) 2002-03-13
ES2219342T3 (es) 2004-12-01
CY1105750T1 (el) 2010-12-22
CZ295623B6 (cs) 2005-09-14
DK1185272T3 (da) 2004-08-09
ES2330774T3 (es) 2009-12-15
ZA200110485B (en) 2003-06-30
KR20020008847A (ko) 2002-01-31
US7371756B2 (en) 2008-05-13
PT1736158E (pt) 2009-11-11
CA2372668A1 (en) 2000-12-07
CZ20014226A3 (cs) 2002-03-13
EP1185272B1 (en) 2004-04-07
US20100063062A1 (en) 2010-03-11
SK16462001A3 (sk) 2002-02-05
RU2237477C2 (ru) 2004-10-10
AU5066300A (en) 2000-12-18
TR200103361T2 (tr) 2002-05-21
JP4884588B2 (ja) 2012-02-29
ATE263564T1 (de) 2004-04-15
HUP0201275A3 (en) 2004-04-28
SK287851B6 (sk) 2012-01-04
PL199516B1 (pl) 2008-09-30
SI1185272T1 (en) 2004-12-31
CA2615271A1 (en) 2000-12-07
NO20061562L (no) 2001-11-26
HK1048444A1 (en) 2003-04-04
PL200490B1 (pl) 2009-01-30
NO322120B1 (no) 2006-08-14
MXPA01012172A (es) 2002-07-22

Similar Documents

Publication Publication Date Title
DK1736158T3 (da) Anvendel af 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin samt de fysiologiske acceptable salte deraf
NL300952I2 (nl) Peramivir en farmaceutisch aanvaardbare zouten daarvan
DE60113865D1 (de) Piperazin derivate
NO20020307D0 (no) N-(indolkarbonyl)piperazinderivater
PL356769A1 (en) Novel heterocyclic compounds and salts thereof and medicinal use of the same
DE60134338D1 (de) Piperazin-derivate
ATE258928T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
DE60018978D1 (de) Benutzerauthentifiezierung in medizinischen systemen
ATE259796T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
NO20040469L (no) Heterocykliske forbindelser samt fremstilling og anvendelse derav
FI973816A0 (fi) Polypropen med hoeg smaeltstyrka
DE60018509D1 (de) Wegwerfwindel
DE60030399D1 (de) Wegwerfwindel
NO20023787L (no) Piperazin- og piperidinderivater
DE60024528D1 (de) Wegwerfwindel
DE60040712D1 (de) Wegwerfwindel
ATE267183T1 (de) Piperazine und piperidine derivate
FR2794019B1 (fr) Implant d'osteosynthese
DE69930543D1 (de) Piperazin-derivate
NO20025510L (no) Dibenzoazulen-derivater samt anvendelse derav
DE60025453D1 (de) Wegwerfwindel
DK1106607T3 (da) Uracilforbindelser og anvendelse deraf
DE60014751D1 (de) Wegwerfwindel
DE60026784D1 (de) Wegwerfwindel
ZA200309513B (en) Novel heterocyclic derivatives and medicinal use thereof.